AN UNBIASED VIEW OF GR 113808

quinupristin/dalfopristin will raise the level or influence of avanafil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. CYP3A4 inhibitors may lessen avanafil clearance rising systemic exposure to avanafil; elevated levels may possibly lead to elevated related adverse occasions; the most proposed dose of STENDRA is 50